Global REM Sleep Behavior Disorder Market

1. Summary

The Global REM Sleep Behavior Disorder Market was valued at $2.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.2% CAGR, to an estimated market size of $3.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The Global REM Sleep Behavior Disorder (RBD) market encompasses the diagnosis, monitoring, and therapeutic management of a parasomnia characterized by the loss of normal skeletal muscle atonia during REM sleep. The scope includes pharmacological treatments (primarily off-label medications like clonazepam and melatonin), diagnostic services such as polysomnography (PSG), and emerging wearable monitoring devices. It excludes general sleep aids like mattresses and pillows but includes specialized clinical pathways for identifying RBD as a prodromal marker for neurodegenerative diseases.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the REM Sleep Behavior Disorder Market in the period 2025-30:

• The recognition of RBD as a critical prodromal biomarker for neurodegenerative alpha-synucleinopathies, such as Parkinson’s disease and Lewy body dementia, is driving early clinical intervention.
• Integration of Artificial Intelligence (AI) and machine learning into polysomnography systems is enhancing diagnostic accuracy through automated sleep scoring and movement pattern analysis.
• A significant shift toward home-based monitoring and wearable technology is addressing the cost and scalability limitations of traditional in-lab sleep studies.
• The rapidly aging global population is expanding the primary patient demographic, as RBD prevalence increases significantly in adults over the age of 60.
• There is a high level of unmet medical need due to the current lack of FDA-approved therapies specifically for RBD, fueling research into novel GABA and serotonin modulators.
• Advancements in non-invasive biomarkers, including alpha-synuclein testing via skin biopsies and saliva, are facilitating earlier and more precise diagnosis.
• Growing clinical awareness of medication-induced RBD, particularly from SSRI and SNRI antidepressants, is influencing secondary RBD management strategies.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: